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1. Pre-analytical and analytical characteristics of published circRNA tissue expression 
studies in cancers 
 
Supplemental Table S1. Analytical characteristics of 25 randomly selected studies of circRNA 




Cancer type Tissue 
collection 
and storage 





1 Li et al., 2015 
[1] 
Gastric cancer 5 No GAPDH 
2 Ahmed et al., 
2016 [2] 
Ovarian cancer 1 No ACTB, 
GAPDH 
3 Lu et al., 2017 
[3] 








1 No GAPDH 
5 Dang et al., 
2017 [5] 








1 No U6, GAPDH 








8 Chen et al, 
2017 [8] 
Gastric cancer 5 No GAPDH 




4 No GAPDH 




1 No ACTB 








12 Huang et al., 
2019 [12] 
Kidney cancer 4 No GAPDH  
13 Chen et al., 
2019 [13] 
Glioma 0 No GAPDH 
14 Lu et al., 2020 
[14] 
Colon cancer 4 No GAPDH 
15 Jin et al., 2020 
[15] 
Melanoma 3 No GAPDH 




2 No Only Cq based 
17 Sun et al., 
2020 [17] 
Thyroid cancer 2 No GAPDH 




3 No GAPDH 




3 No ACTB 
20 Li et al, 2020 
[20] 
Osteosarcoma 0 No GAPDH 
 




Cancer type Tissue 
collection 
and storage 















22 Kong et al., 
2020 [22] 
Prostate cancer 0 No ACTB 
23 Meng et al., 
2020 [23] 
Cervical cancer 0 No GAPDH 




0 No GAPDH 
25 Yu et al., 
2020 [25] 
Bladder cancer 0 No GAPDH 
a The studies were reviewed only with regard to the data of tissue collection and storage, RNA 
integrity, and reference standards for normalization. 
b Information on tissue collection and storage in the studies was categorized with following 
specifications: 0=no detailed information regarding collection and storage; 1=fresh frozen; 2=stored at 
-80 °C; 3=collected and stored in liquid nitrogen until use; 4=collected in liquid nitrogen and stored at 
-80 °C until use; 5=collected in RNA storage solution and stored at -80 °C until use. 
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2. Clinicopathological characteristics of the study own cohorts in relation to the degraded 
RNA samples  
 
Supplemental Table S2. Clinicopathological characteristics of patients suffering from clear cell renal 
cell carcinoma. 
Characteristics Total Patient samples 
with RIN ≤6 
 
Patient samples 
with RIN >6 
P value a 
 
Patients, no. (%) 61 (100) 28 (46) 33 (54)  
Sex, female/male; no. (%) 20/41 (33/67) 8/20 (29/71) 12/21 (36/64) 0.591 
 
Age, years, median (IQR) 61 (56-69) 60 (57–66) 64 (56–70) 0.311 
 









































































Tumor size, mm, median (IQR) 
 
65 (49-87) 75 (60-118) 60 (47-81) 0.309 





































a Calculated with Fisher's exact test, Chi-squared test or Mann-Whitney U test between the two RIN 
groups without considering unclassified data. 
b TNM stage grouping according to UICC classification system. 
G: histopathological grading according to Fuhrman; IQR: interquartile range; pT: pathological tumor 
classification; RIN: RNA integrity number. 
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Supplemental Table S3. Clinicopathological characteristics of patients suffering from prostate 
cancer. 
a Calculated with Fisher's exact test, Chi-squared test or Mann-Whitney U test between the two RIN 
groups without considering unclassified data. 
DRE: digital rectal examination; IQR: interquartile range; ISUP: histopathological grade system based 
on Gleason score according to the International Society of Urologic Pathology; pN: lymph node status; 
PSA: total prostate specific antigen; pT: pathological tumor classification; RIN: RNA integrity 
number. 
  
 Total Patient samples 
with RIN ≤6 
Patient samples 
with RIN >6 
P valuea 
 
Patients, no. (%) 57 (100) 26 (46) 31 (54)  
Age, years, median (IQR) 67 (62–71) 71 (66–73) 65 (61–69) 0.004 
PSA, µg/L, median (IQR) 8.3 (5.95–14.0)  11.4 (6.7–17.8) 7.4 (5.7–12.2) 0.157 
Prostate volume, cm3, 
median (IQR) 
31 (25–38) 32 (28–36) 30 (25–38) 0.539 
DRE, no. (%)     
non-suspicious 30 (53) 13 (50) 17 (55) 1.000 
suspicious 16 (28) 7 (27) 9 (29)  
unclassified  11 (19) 6 (23) 5 (16)  
pT status, no. (%)     
pT2a 1 (2) 1 (4) 0 (0) 0.726 
pT2c 22 (39) 10 (38) 12 (39)  
pT3a 14 (25) 6 (23)  8 (26)  
pT3b 19 (33) 8 (31) 11 (35)  
unclassified 1 (2) 1 (4) 0 (0)  
ISUP Grade groups, no. (%)     
1 8 (14) 2 (7.5) 6 (19) 0.150 
2 19 (33) 9 (35) 10 (32)  
3 15 (26) 4 (15) 11 (35)  
4 5 (9) 3 (12) 2 (7)  
5 8 (14) 6 (23) 2 (7)  
unclassified 2 (4) 2 (7.5) 0 (0)  
pN status, no. (%)     
pN0/Nx 51 (89) 22 (85) 29 (94) 0.396 
pN1 6 (11) 4(15) 2 (6)  
Surgical margin, no. (%)     
negative 28 (49) 12 (46) 16 (52) 1.000 
positive 28 (49) 13 (50) 15 (48)  
unclassified 1 (2) 1 (0) 0 (0)  
 
Supplementary Material - 6 - 
 
3. RT-qPCR methodology  
 
Supplemental Table S4. MIQE checklist according to Bustin et al. [26]. 




WHERE; COMMENT  
EXPERIMENTAL DESIGN    
Definition of experimental 
and control groups 
E Yes Main text: Materials and Methods; Tables 
S2 and S3 
Number within each group E Yes Main text: Materials and Methods; Results; 
Tables S2 and S3 
Assay carried out by core lab 
or investigator's lab? 
D Yes Investigator's lab 
Acknowledgement of authors' 
contributions  
D Yes Section Acknowledgements 
SAMPLE    
Description E Yes Main text: Results; Materials and Methods. 
Volume/mass of sample 
processed 
D Yes Main text: Results; Materials and Methods  
Microdissection or 
macrodissection 
E Yes Main text: Materials and Methods  
Processing procedure E Yes Main text: Materials and Methods  
If frozen - how and how 
quickly? 
E Yes Main text: Materials and Methods  
If fixed - with what, how 
quickly? 
E Yes Main text: Materials and Methods 
Sample storage conditions 
and duration (esp. for FFPE 
samples) 
E Yes Main text: Materials and Methods  
NUCLEIC ACID EXTRACTION   
Procedure and/or 
instrumentation 
E Yes Main text: Materials and Methods  
Name of kit and details of any 
modifications 
E Yes Main text: Materials and Methods  
Source of additional reagents 
used  
D N/A  Not used 
Details of DNase or RNase 
treatment 
E Yes Main text: Materials and Methods: RNA 
extraction, on-column DNase digestion 
Contamination assessment 
(DNA or RNA) 
E Yes Main text: Methods and Materials. 
Supplementary Material: Genomic DNA 
contamination was excluded by control 
experiments without reverse transcription of 
RNA for all target genes 
Nucleic acid quantification  E Yes Main text: Materials and Methods, 
spectrophotometric 
Instrument and method E Yes Main text: Materials and Methods, 
Nanodrop 
Purity (A260/A280)  D Yes Main text: Materials and Methods 
Yield D Yes Main text: Materials and Methods 
RNA integrity 
method/instrument 
E Yes Main text: Materials and Methods: RIN; 
Bioanalyzer 2100, Agilent RNA 6000 
Nano Chip Kit 
RIN/RQI or Cq of 3' and 5' 
transcripts  
E Yes Main text: Materials and Methods: RIN; 
Bioanalyzer 2100, Agilent; see Figure S1 
Electrophoresis traces D Yes see RNA integrity: Agilent electrophoresis 
Inhibition testing (Cq 
dilutions, spike or other)  
E Yes Supplementary Material: Cq dilution, see 
standard curve characteristics in 
Supplemental Table S10  
REVERSE TRANSCRIPTION   
Complete reaction conditions E Yes Main text: Materials and Methods; 
Supplementary Material: RT-qPCR 
methodology, cDNA synthesis in 3.1.1 
Amount of RNA and reaction 
volume 
E Yes Main text: Materials and Methods; 
Supplementary Material: RT-qPCR 
methodology, cDNA synthesis in 3.1.1 
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Priming oligonucleotide (if 
using GSP) and concentration 
E Yes Main text: Materials and Methods; 
Supplementary Material: RT-qPCR 
methodology, cDNA synthesis in 3.1.1 
Reverse transcriptase and 
concentration 
E Yes Main text: Materials and Methods; 
Supplementary Material: RT-qPCR 
methodology, cDNA synthesis in 3.1.1 
Temperature and time E Yes Main text: Materials and Methods; 
Supplementary Material: RT-qPCR 
methodology, cDNA synthesis in 3.1.1 
Manufacturer of reagents and 
catalogue numbers 
D Yes Main text: Materials and Methods; 
Supplementary Material: RT-qPCR 
methodology, cDNA synthesis in 3.1.1.  
Cqs with and without RT D Yes Supplementary Material: RT-qPCR 
methodology: neg. results; see also 
comment on DNase treatment. There were 
no Cqs <40 in reactions without RT 
Storage conditions of cDNA D Yes Main text. Materials and Methods; storage 
at -20 °C 
qPCR TARGET INFORMATION   
Gene symbols E Yes Main text: Table 1; Supplementary 
Material: Table S6–S8 
If multiplex, efficiency and 
LOD of each assay. 
E N/A Only singleplex qPCR 
Sequence accession number E Yes Main text: Table 1; Supplementary 
Material: Supplemental Table S6–S9.  
Location of amplicon D Yes Supplementary Material: Supplemental 
Tables S6-S7  
Amplicon length E Yes Supplementary Material: Supplemental 
Tables S6-S7; Bioanalyzer 2100 DNA1000 
expert series II Chip analysis: Figure S2 
In silico specificity screen 
(BLAST, etc) 
E Yes Main text: Materials and Methods; 
Supplementary Material: RT-qPCR 
methodology. All primers and amplicons 
were checked by screens in different 
databases, see URL links in 3.2.1 
Pseudogenes, 
retropseudogenes or other 
homologs? 
D N/A  
Sequence alignment D Yes Supplementary Material: RT-qPCR 
methodology, see URL links as mentioned 
above in 3.2.1. Using NCBI-based 
Megablast against standard Nucleotide 
collection databases (nr/nt) and RefSeq, 
filtered Homo sapiens (taxid.9606). 
Analyses using databases circBase and 
CircInteractome 
Secondary structure analysis 
of amplicon 
D No  
Location of each primer by 
exon or intron (if applicable) 
E Yes Supplementary Material: Supplemental 
Tables S6-S7. Analysis of different 
databases: Ensembl NCBI nucleotide, 
circBAse and CircInteractome 
What splice variants are 
targeted? 
E N/A  
qPCR OLIGONUCLEOTIDES   
Primer sequences E Yes Supplementary Material: RT-qPCR 
methodology with Supplemental Tables S8  
RTPrimerDB Identification 
Number  
D N/A   
Probe sequences D Yes Supplementary Material: RT-qPCR 
methodology, UPL probes only for ALAS1 
and HPRT1 in 3.2.1 
Location and identity of any 
modifications 
E N/A No modifications 
Manufacturer of 
oligonucleotides 
D Yes TIB MolBiol (Berlin, Germany); Applied 
Biosystems; Probes from Roche  
Purification method D Yes TIB MolBiol: GSF purification 
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qPCR PROTOCOL    
Complete reaction conditions E Yes Main text: Materials and Methods. 
Supplementary Material: RT-qPCR 
methodology 
Reaction volume and amount 
of cDNA/DNA 
E Yes Main text: Materials and Methods. 
Supplementary Material: RT-qPCR 
methodology  
Primer, (probe), Mg++ and 
dNTP concentrations 
E Yes Main text: Materials and Methods. 
Supplementary Material: RT-qPCR 
methodology 
Polymerase identity and 
concentration  
E Yes Main text: Materials and Methods. 
Supplementary Material: RT-qPCR 
methodology 
Buffer/kit identity and 
manufacturer  
E Yes Main text: Materials and Methods. 
Supplementary Material: RT-qPCR 
methodology 
Exact chemical constitution of 
the buffer 
D No The manufacturer does not provide this 
information 
Additives (SYBR Green I, 
DMSO, etc.) 
E Yes Main text: Materials and Methods. 
Supplementary Material: RT-qPCR 
methodology, SYBR Green in ready-to-use 
soft master 
Manufacturer of plates/tubes 
and catalogue number 
D Yes Supplementary Material: RT-qPCR 
methodology in 3.1.1 and 3.2.1  
Complete thermocycling 
parameters 
E Yes Main text: Materials and Methods. 
Supplementary Material: RT-qPCR 
methodology for all runs in 3.2.1 
Reaction setup 
(manual/robotic) 
D Yes Manual setup  
Manufacturer of qPCR 
instrument 
E Yes Main text: Materials and Methods: 
LightCycler 480 (Roche)  
qPCR VALIDATION    
Evidence of optimisation  D Yes Supplementary Material: RT-qPCR 
methodology: all run conditions of qPCRs  
were optimized, for circEGLN3, linEGLN3, 
circRHOBTB3, and linRHOBTB3 see also 
ref. [27]; for reference genes [28, 29] with 
primers as indicated in Table S8; for 
circCSNK1G3 see Supplemental Figure S2 
according to Chen et al. [30].  
Specificity (gel, sequence,  
melt, or digest) 
E Yes Supplementary Material: RT-qPCR 
methodology with Supplemental Figure S2 
for circEGLN3, circRHOBTB3, and 
circCSNK1G3 (Agilent electropherogram, 
melting curves on LightCycler); other 
circRNAs also in ref. [27]) 
For SYBR Green I, Cq of the 
NTC 
E Yes Main text: Materials and Methods; 
Supplementary Material: RT-qPCR 
methodology, no Cqs <40 in reaction 
without RT 
Standard curves with slope 
and y-intercept 
E Yes Supplementary Material: RT-qPCR 
methodology; 3.3. Performance data, Table 
S10 
PCR efficiency calculated 
from slope 
E Yes Supplementary Material: RT-qPCR 
methodology; 3.3. Performance data, Table 
S10 
Confidence interval for PCR 
efficiency or standard error 
D Yes Supplementary Material: RT-qPCR 
methodology; 3.3. Performance data, Table 
S10 
r2 of standard curve E N/A Not provided by the LC480 software 
Linear dynamic range E Yes Supplementary Material: RT-qPCR 
methodology; 3.3. Performance data, Table 
S10 with endpoints of standard curves 
Cq variation at lower limit E Yes Supplementary Material: RT-qPCR 
methodology, Supplemental Table S10 with 
Cq range of the measured samples, only 
two samples (see Table S10) with outside 
of the dynamic range  
 




D N/A   
Evidence for limit of 
detection  
E Yes Supplementary Material: RT-qPCR 
methodology, Supplemental Table S10: 
samples with Cq values in the dynamic 
range of the standard curves except two 
samples (see Table S10) 
If multiplex, efficiency and 
LOD of each assay. 
E N/A  No multiplex assays 
DATA ANALYSIS    
qPCR analysis program 
(source, version) 
E Yes Main text: Materials and Methods. 
Supplementary Material: RT-PCR 
methodology. 3.3. Performance data with 
Supplemental Table S10 (LightCycler 480 
software, release 1.5.1.62 using the “second 
derivative maximum” method); qbase+ 
software, version 3.2 (Biogazelle, 
Zwijnaarde, Belgium) for generation of 
relative quantities (RQs) and normalized 
relative quantities (NRQs) 
Cq method determination E Yes 
Outlier identification and 
disposition 
E N/A 2 samples with Cqs outside of the standard 
curve were included in the study 
Results of NTCs  E Yes Main text: Materials and Methods; 
Supplementary Material: RT-PCR 
methodology, no Cqs <40 in reaction 
without RT 
Justification of number and 
choice of reference genes 
E Yes Main text: Materials and Methods; Results. 
Supplementary Material: RT-PCR 
methodology with reference genes PPIA 
and TBP according to [28] and ALAS1 and 
HPRT1 according to [29] 
Description of normalisation 
method 
E Yes Main text: Materials and Methods; 
Supplementary Material: RT-PCR 
methodology: cancer-specific reference 
genes PPIA and TBP for kidney cancer, 
ALAS1 and HPRT1 for prostate cancer, see 
previous comment. Use of the software 
qbase+ 
Number and concordance of 
biological replicates 
D Yes Concordance is reflected by the 
performance data given in the repeatability 
and reproducibility data in Table S11 
Number and stage (RT or 
qPCR) of technical replicates 
E Yes Main text: Materials and Methods; 
Supplementary Material: RT-PCR 




E Yes Main text: Materials and Methods; 
Supplementary Material: RT-PCR 




D Yes Main text: Materials and Methods; 
Supplementary Material: RT-PCR 
methodology, 3.3. Performance data, Table 
S11 
Power analysis D Yes Main text: Materials and Methods: Data 
analysis 
Statistical methods for result 
significance 
E Yes Main text: Materials and Methods: Data 
analysis. Results, figures, and figure 
legends  
Software (source, version) E Yes Main text: Materials and Methods: Data 
analysis, statistical analysis 
Cq or raw data submission 
using RDML 
D No  
 E: essential information; D: desirable information if available; N/A: not applicable. 
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1. A-498 cell: RNA degradation 
 
 
2. HEK-293 cell: RNA degradation 
 
 
3. Renal tissue pool RNA: RNA degradation 
 
 
Supplemental Figure S1. Bioanalyzer 2100 results of RNA samples after heat incubation at 80 °C. 
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3.1. cDNA synthesis 
3.1.1. cDNA synthesis of circRNAs and mRNAs 
Maxima First Strand cDNA Synthesis Kit for RT-qPCR (Thermo Scientific, Waltham, MA, USA; 
Cat.No. K1642) was used in final reaction volume of 20 µL according to the following protocol: 
 
Supplemental Table S5A. cDNA synthesis using the Maxima First Strand cDNA Synthesis Kit.  
Volume 
(µL) 
Reagent/Sample Components  
4 5X Reaction Mix Reaction buffer, dNTPs, oligo(dT)18, and random 
hexamer primers without specified concentration 
2 Maxima Enzyme Mix Maxima Reverse Transcriptase (M-MuLV RT) and 
Thermo Scientific™ RiboLock™ RNase Inhibitor 
2 Total RNA (500 ng) Diluted RNA (gDNA free); see RNA isolation 
12 Water, nuclease free  
The RT reaction was carried out in 0.2 mL PCR Soft Tubes (Biozym Scientific GmbH, Germany; 
Article No. 711080) in a thermal block cycler (Biometra GmbH, Göttingen, Germany) as follows: 10 
min at 25 °C, followed by 15 min at 50 °C, and terminated by heating at 85 °C for 5 min; end 4 °C. All 
cDNA samples were stored at -20 °C until qPCR analysis (see the following Section 3.2.1). 
 As explained in the Main text: Materials and Methods, cDNA synthesis, we used the 
Transcriptor First Strand cDNA Synthesis Kit (Life Science Roche, Mannheim, Germany; Cat. No. 
04379012001) for the cDNA synthesis of circRNAs for the comparative priming with random 
hexamer and oligo(dT)18 primers according to the following protocol: 
 
Supplemental Table S5B. cDNA synthesis using Transcriptor First Strand cDNA Synthesis Kit. 
Volume 
(µL) 
Reagent/Sample Components and final (1x) concentration 










9 or 10 Water, PCR Grade  
4 Transcriptor Reverse Transcriptase 
Reaction Buffer, 5x conc. 
50 mM Tris/HCl, 30 mM KCl, 8 mM MgCl2 
0.5 Protector RNase Inhibitor 20 U 
2 Deoxynucleotide Mix 1 mM each 
0.5 Transcriptor Reverse Transcriptase  10 U 
The RT reaction conditions were primer dependent. Using random hexamer primers: 10 min at 25 °C, 
followed by 30 min at 55 °C and inactivation for 5 min at 85 °C; end 4 °C. Using anchored-oligo(dT)18 
primers, the initial incubation step was omitted, the other temperature steps were identical. Both 
cDNA samples were stored at -20 °C until qPCR analysis (see the following Section 3.2.1). 
 
3.1.2. cDNA synthesis of microRNAs 
The TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) was used according to the 
manufacturer’s instructions. Using a Biometra thermal block cycler as mentioned above, the cDNA 
synthesis was performed in a reaction mixture containing 10 ng of total RNA, 15 nmol of dNTP mix, 
50 U AB Multiscribe Reverse Transcriptase, 1x microRNA specific stem-looped RT-primer (AB), 
3.75 U AB RNase Inhibitor, and 1x RT buffer. The steps were the following: priming at 16 °C for 
30 min, transcription at 42 °C for 30 min, and enzyme inactivation at 85 °C for 5 min. All cDNA 
samples were stored at -20 °C until qPCR analysis. 
 
3.2. qPCR- measurements 
3.2.1. Quantification of circRNAs and mRNAs 
All real-time qPCR runs were performed on the LightCycler 480 Instrument (Roche Molecular 
Systems, Mannheim, Germany) in white 96-well plates (Cat.No. 04729692001) using at least technical 
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duplicates and resulting mean values were used for further calculations. Maxima SYBR Green qPCR 
Master Mix (2X) (Thermo Scientific; Cat.No. K0252) was used. The determination of circRNAs is 
based on the measurement of their specific backsplice junctions using divergent primers [31]. The 
backsplice junction sequences of the three circRNAs measured in this study and the amplicon 
characteristics are listed in Supplemental Table S6; information regarding the linear counterparts of 
the circRNAs and the normalizers are given in Supplemental Table S7. 
 All primers of circRNAs (divergent) and mRNAs (convergent) were designed using the 
Primer3 tool (http://bioinfo.ut.ee/primer3/) or with Roche/UPL ProbeFinder web-based software 
(https://lifescience.roche.com/en_de/brands/universal-probe-library.html#assay-design-center) and are 
compiled in Supplemental Table S8 [32]. Primers were synthesized by TIB Molbiol GmbH (Berlin, 
Germany). Expression of mRNAs of peptidylprolyl isomerase (PPIA), TATA-box binding protein 
(TBP), 5'-aminolevulinate synthase 1 (ALAS1), and hypoxanthine phosphoribosyltransferase 1 
(HPRT1) was used for normalization as these genes are generally used as normalizers in expression 
studies of clear cell renal cell carcinoma and prostate cancer [28, 29]. PPIA was quantified by 
QuantiTect Primer assay from Qiagen (Supplemental Table S7) in SYBR Green assay format, ALAS1 
and HPRT1 were measured with Universal ProbeLibrary-probes (ALAS1 Probe #40 Prod. No: 
04687990001; HPRT1 Probe #22 Prod. No: 04686969001) and LightCycler 480 Probes Master from 
Roche (Prod. No. 04707494001) in hydrolysis probe assay format on the LightCycler 480 
(Supplemental Table S8). Quantitative PCR data analysis was done using qbase+ software, version 3.2 
(Biogazelle, Zwijnaarde, Belgium; www.qbaseplus.com). 
 In general, genes and primer sequences were checked using the following database links: 
https://circinteractome.nia.nih.gov/; http://www.circbase.org/; http://www.ensembl.org (Ensembl 
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Supplemental Table S6. List of backsplice junctions of circRNAs and primers used for RT-qPCR 
detection of circEGLN3, circRHOBTB3, and circCSNK1G3. 
circRNA 
(circBase ID) 












































































a Numbers in brackets indicate the lengths of amplicons detected with Agilent Bioanalyzer 2100. 
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Supplemental Table S7. QPCR target information of the linear counterparts of the circRNAs and 
the reference genes for normalization. 
a Numbers in brackets indicate the lengths of amplicons detected with Agilent Bioanalyzer 2100. 
  
RNA name 
 in the 
manuscript 
Official gene 
symbol of the 














linEGLN3 EGLN3, egl-9 
family hypoxia 
inducible factor 3 
NM_022073.4 Ex4(F)/Ex5(R) 1037 88 
(92) 




NM_014899.4 Ex5(F)/Ex6(R) 3045 94 
(96) 
linCSNK1G3 CSNK1G3, 




Ex6(F)/Ex8(R) 273/1901 142 
(144) 
PPIA PPIA,  
peptidylprolyl 
isomerase 
NM_021130.5  QuantiTect Primer 
Assay (Cat.No.: QT-
00052311) in Ex 4/5 
1412 121 
(123) 
TBP TBP, TATA-box 
binding protein 













NM_000194.3 Ex3(F)/Ex4+5 (R) 11100/3657 126 
(119) 
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Supplemental Table S8. List of primers.  



































Convergent Primers Primer sequences (5’… 3’) 
NM_022073.4 linEGLN3-Fa CTGTCTGGTACTTTGATGCTGAA 
NM_022073.4 linEGLN3-Ra TCAGTGAGGGCAGATTCAGTT 
NM_014899.4 linRHOBTB3-Fa CCACCTCAACTTGAACAACCA 
NM_014899.4 linRHOBTB3-Ra GGCAGCAGAACAGCAAGTTA 
NM_001044723.2 linCSNK1G3-Fb TGAGAGGCAGTCTTCCTTGG 
NM_001044723.2 linCSNK1G3-Rb ACATAACGAAGATATGTTGCCATT 
NM_021130.5 PPIA-F+R mix QuantiTect Primer Assay (QT00052311), Qiagen 
   
NM_003194.5 TBP-Fd TTCGGAGAGTTCTGGGATTGTA 
NM_003194.5 TBP-Rd TGGACTGTTCTTCACTCTTGGC 
NM_000688.6 ALAS1-Fe GAAATGAATGCCGTGAGGAA 
NM_000688.6 ALAS1-Re CCTCCATCGGTTTTCACACT  
NM_000194.3 HPRT1-Fe TGATAGATCCATTCCTATGACTGTAGA 
NM_000194.3 HPRT1-Re AAGACATTCTTTCCAGTTAAAGTTGAG 
a According to Franz et al. [27]. 
b According to Chen et. [30]. 
c According to Memczak et al. [33]. 
d According to Jung et al. [28]. 
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Protocols for all LightCycler runs in SYBR Green and Probe assay format 
  
qPCR reaction mix for all SYBR Green assays 
Volume (µL) Reagent/Sample Components  
5 Maxima SYBR Green 
qPCR Master Mix (2X) 
Maxima Hot Start Taq DNA Polymerase, dNTPs (also dUTP) and SYBR 
Green I in an optimized PCR buffer 
2 Primer Mixa Forward and reverse primer mix, final concentration each 0.250 µM 
1 cDNAb Un- or prediluted 
2 Water, nuclease free  
Total volume 10 µL  
a For PPIA qPCR, F+R primer mix included in QuantiTect Primer assay (Qiagen) was used; all other 
qPCR primers were synthesized by TIB Molbiol. 
b Undiluted cDNA input for qPCR of circCSNK1G3 and linCSNK1G3 and 1:10 prediluted cDNA 
input for qPCR of circ- and linEGLN3, circ- and linRHOBTB3, PPIA and TBP. 
 
LightCycler 480 SYBR Green assay run templates 
Setup 
Block type Reaction volume (µL) 
 96 10 
Detection format Excitation filter  Emission filter 
 SYBR Green 483 nm 533 nm 
Programs 
Program names Cycles Analysis mode 
 Pre-incubation 1 None 
 Amplification 45 Quantification 
 Melting curve 1 Melting curve 
 Cooling 1 None 
The setup and programs are equal for all assays in SYBR Green detection format. 
 
LightCycler 480 SYBR Green assay run template for circEGLN3 
Temperature targets 
 Target (°C) Acquisition mode Hold time (s) Ramp rate (°C/s) Acquisitions (per °C) 
 Pre-incubation 95 None 600 4.4 - 
 Amplification 95 None 15 4.4 - 
 60 None 30 2.2 - 
 79 Single 2 4.4 - 
 Melting curve 95 None 5 4.4 - 
 65 None 60 2.2 - 
 95 Continuous - 0.11 5 
 Cooling 40 None 30 1.5 - 
 
LightCycler 480 SYBR Green assay run template for linEGLN3, linCSNK1G3, lin- and 
circRHOBTB3 qPCR 
Temperature targets 
 Target (°C) Acquisition mode Hold time (s) Ramp rate (°C/s) Acquisitions (per °C) 
 Pre-incubation 95 None 600 4.4 - 
 Amplification 95 None 15 4.4 - 
 60 None 15 2,2 - 
 70 Single 15 4.4 - 
 Melting curve 95 None 5 4.4 - 
 65 None 60 2.2 - 
 95 Continuous - 0.11 5 




Supplementary Material - 17 - 
 
LightCycler 480 SYBR Green assay run template for circCSNK1G3 
Temperature targets 
 Target (°C) Acquisition mode Hold time (s) Ramp rate (°C/s) Acquisitions (per °C) 
 Pre-incubation 95 None 600 4.4 - 
 Amplification 95 None 10 4.4 - 
 60 None 30 2.2 - 
 72 Single 2 4.4 - 
 Melting curve 95 None 5 4.4 - 
 65 None 60 2.2 - 
 95 Continuous - 0.11 5 
 Cooling 40 None 30 1.5 - 
 
 
LightCycler 480 SYBR Green assay run template for reference genes PPIA and TBP 
Temperature targets 
 Target (°C) Acquisition mode Hold time (s) Ramp rate (°C/s) Acquisitions (per °C) 
 Pre-incubation 95 None 900 4.4 - 
 Amplification 95 None 15 4.4 - 
 58 None 20 1.0 - 
 72 None 20 4.4  
 79 Single 2 4.4 - 
 Melting curve 92 None 5 4.4 - 
 65 None 60 2.2 - 
 95 Continuous - 0.11 5 
 Cooling 40 None 30 1.5 - 
 
 
qPCR reaction mix for Probe assays for the reference genes ALAS1 and HPRT1  
Volume (µL) Reagent/Sample Components  
5 2x LightCycler 480 
Probes Master 
Mix containing FastStart Taq DNA Polymerase, reaction buffer, dNTP 
mix (with dUTP instead of dTTP), and 6.4 mM MgCl2 
1 Primer Mix Forward and reverse primer mix, final concentration each 0.250 µM 
1 Probe Roche UPL Probe #40 for ALAS1 or #22 for HPRT1, final 
concentration 0.2 µM 
1 cDNA Undiluted 
2 Water, nuclease free  
Total volume 10 µL  
 
LightCycler 480 Probe assay run template for the reference genes ALAS1 and HPRT1 
Setup 
Block type Reaction volume (µL) 
 96 10 
Detection format Excitation filter  Emission filter 
 Mono Color Hydrolysis Probe 483 nm 533 nm 
Programs 
Program names Cycles Analysis mode 
 Pre-incubation 1 None 
 Amplification 45 Quantification 
 Cooling 1 None 
Temperature targets 
 Target (°C) Acquisition mode Hold time (s) Ramp rate (°C/s) Acquisitions (per °C) 
 Pre-incubation 95 None 600 4.4 - 
 Amplification 95 None 10 4.4 - 
 60 None 30 2.2 - 
 72 Single 1 4.4 - 
 Cooling 40 None 30 1.5 - 
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3.2.2. Quantification of miRNAs 
TaqMan MiRNA Assays (Applied Biosystems) were used for the detection of mature miRNAs 
let-7a-5p, miR-17-5p, and miR-210-3p (Supplemental Table 9). Technical details corresponded with 
analysis parameters given in our previous reports [34-37]. 
 
Supplemental Table S9. TaqMan MicroRNA Assays (Applied Biosystems; Assay name, Assay ID) 
for the measurement of mature miRNAs characterized by the miRBase accession number, the 
miRBase IDs, and the sequences in reference to the miRBase 22 version. 




miRBase ID  Sequence 
hsa-let-7a 000377 MIMAT0000062 hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU 
hsa-miR-17 002308 MIMAT0000070 hsa-miR-17-5p CAAAGUGCUUACAGUGCAGGUAG 
hsa-miR-210 000512 MIMAT0000267 hsa-miR-210-3p  CUGUGCGUGUGACAGCGGCUGA 
 
The qPCR reaction mixture of 10 µL contained: 1 µL miRNA-specific cDNA, 5 µL TaqMan 2x 
Universal PCR Master Mix No AmpErase UNG, 0.5 µL gene-specific TaqMan MicroRNA real-time 
PCR-Assay solution (20x), and 3.5 µL nuclease-free water. Following cycling conditions were set: 
initial activation of Taq polymerase at 95 °C for 10 min, amplification steps: denaturation at 95 °C, 
15 s, annealing/elongation at 60 °C for 1 min with fluorescence acquisition, and final cooling step at 
40 °C for 1 min. All non-template controls were negative. 
 
 
3.3. Performance data of the assays 
Analytical specificity and characteristics of circEGLN3, circRHOBTB3, their linear counterparts, the 
reference genes, and the three miRNAs were already reported in our previous publication of circRNAs 
in ccRCC (Sanger sequencing, melting-point analysis, PCR-product specificity) or in other preceding 
publications [27-29, 35]. For the PCa-specific circRNA circCSNK1G3, analytical specificity data are 
given in the article by Chen et al. [30]. The analytical specificity of circCSNK1G3 was confirmed by 
the usual tests including Sanger sequencing. In Figure S2, its melting-point analysis and PCR-product 
specificity is shown together with those of circEGLN3 and circRHOBTB3. In Figure S3, the 
decreased cDNA synthesis of the circRNAs in the clinical samples with oligo(dT) primers is shown in 
comparison to the cDNA synthesis with random hexamer primers, indicating that the circRNAs have 
no poly(A) tail. For all assays used in this study, analytical PCR characteristics are presented in Table 
S10 and data of repeatability and reproducibility in Table S11. 
  
 




















































Supplemental Figure S2. Amplicon analyses of circCSNK1G3, circEGLN3, and circRHOBTB3 with 
Agilent Bioanalyzer 2100 (gel view and electropherogram) and with Roche LightCycler 480 
Instrument (melting curve analysis). For qPCR of circCSNK1G3, published primers from Chen et al. 
[30] were used. 
  
 





















Supplemental Figure S3. Random vs. oligo(dT) primers for cDNA synthesis of circEGLN3, 
circCSNK1G3, and circRHOBTB3. The results of qPCR measurements showed that the relative 
expression was markedly decreased in all circRNAs (at least n = 3 of tissue pools) when using 
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Supplemental Table S10. Characteristics of the qPCR standard curves. 
Standard curves were generated either from diluted cDNAs or from diluted amplicons. Cq values were 
calculated by the LightCycler480 Software Version 1.5.1.62 using the "second derivative maximum" 
method. The efficiency, the slope, intercept, and error of the standard curve as well as the so-called 
dynamic range resulted from LightCycler480 software. 
a PCR efficiency is calculated by the LightCycler480 software using the equation: Efficiency=10-1/slope. 
b The error value is the mean squared error of the single data points fit to the regression line  according 
to the LightCycler 480 operator’s manual. 
c Dynamic range represents the range of Cq values between the highest and the lowest Cq value of the 
generated standard curve. 
d Cq range of the measured samples represents the lowest and highest Cq value measured in all 
samples of the degradation experiments and in the 118 clinical samples. 
e The qPCR standard curves of circRHOBTB3, linEGLN3, and TBP were the same as previously 




Slope y-Intercept Errorb Dynamic 
rangec 
Cq range of 
samplesd 
       
circEGLN3 1.975 -3.385 19,75 0.0174 19.73-35.24 23.12 – 36.51 
2 samples with 
Cq >35 
circRHOBTB3e 2.190 -2.938 20.75 0.0466 20.96 - 32,76 23.05 - 31.13 
circCSNK1G3 1.867 -3.689 21.39 0.0258 20.61 - 32.64 19.73 - 25.57 
1 sample with 
Cq <20,61 
linEGLN3e 1.922 -3.523 14.39 0.0112 14.40 - 34.90 17.82-31.88 
linRHOBTB3 1.929 -3.504 13,50 0.0134 13.48-32.27 19.60 - 29.26 
linCSNK1G3 1.958 -3.426 20.57 0.0204 20.68-34.02 20.30 – 24.55 
ALAS1 1.920 -3.529 18.89 0.0118 18.89-34.18 21.08 - 25.50 
HPRT1 1.863 -3.702 8.881 0.0100 9.01-31.34 23.82 - 28.42 
PPIA 1.928 -3.509 16.13 0.0472 16.08-33.45 17.48 - 22.18 
TBPe 1.840 -3.777 22.51 0.000786 22.20 - 32.20 22.02 - 28.40  
let-7a-5p 1.864 -3.698 22.74 0.00602 21.60 - 33.76 21.53 - 26.19 
miR-17-5p 1.871 -3.676 12.35 0.00698 12.29 - 34.96 22.81 - 25.87 
miR-210-3p 1.968 -3.400 22.97 0.0647 21.92 - 38.50 24.27 - 24.78  
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n Cq values 
Mean ± SD 
(%RSD) 
Relative quantities 
Mean ± SD 
(%RSD) 
circEGLN3 20 26.80 (0.44) 1.879 (8.83) 6 30.56 ± 0.21 (0.68) 0.957 ± 0.092 (9.61) 
circRHOBTB3 20 24.90 (0.37) 1.420 (6.35) 4 24.73 ± 0.14 (0.56) 1.018 ± 0.098 (9.63) 
circCSNK1G3 20 22.12 (0.41) 1.321 (6.56) 5 21.53 ± 0.17 (0.89) 1.291 ± 0.160 (12.4) 
linEGLN3 20 22.83 (0.28) 2.995 (6.16) 6 23.83 ± 0.17 (0.71) 1.006 ± 0.123 (12.2) 
linRHOBTB3 20 21.08 (0.38) 1.187 (5.61) 5 20.51 ± 0.20 (0.97) 1.438 ± 0.198 (13.8) 
linCSNK1G3 20 22.17 (0.36) 1.266 (5.31) 5 21.04 ± 0.17 (0.82) 1.979 ± 0.241 (12.2) 
ALAS1 20 23.66 (0.26) 1.154 (4.19) 4 22.74 ± 0.11 (0.50) 1.675 ± 0.147 (8.78) 
HPRT1 20 25.88 (0.41) 1.441 (7.30) 4 23.86 ± 0.12 (0.50) 3.404 ± 0.284 (8.34) 
PPIA 20 19.36 (0.34) 1.062 (4.78) 7 19.16 ± 0.11 (0.57) 1.003 ± 0.113 (7.88) 
TBP 20 27.27 (0.39) 1.360 (7.53) 7 24.92 ± 0.16 (0.64)  1.005 ± 0.113 (11.2) 
let-7a-5p 20 23.22 (0.49) 1.177 (7.92)    
miR-17-5p 15 24.31 (0.26) 1.384 (4.54)    
miR-210-3p 20 23.87 (0.27) 1.361 (4.56)    
a Using the root mean square method, %RSD values were calculated from duplicate measurements of 
the Cq values and relative quantities, respectively. Relative quantities were calculated using the 2-∆∆Cq 
approach with qbase+ software. 
b Interassay controls; %RSD of Cq values corresponds to the percent relative standard deviation of the 
interassay controls. %RSD of relative quantities corresponds to the percent relative standard deviation 
calculated on basis of  relative quantities using the 2-∆∆Cq approach. 
Cq: quantitation cycle; %RSD: percent relative standard deviation; SD: standard deviation. 
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4. Statistical data regarding the relationship of expression results to RIN values  
 
Table S12. P-values of the expression data calculated as relative quantities and normalized quantities 
in cancer samples classified by the RIN limits 7 or 6. Values for the groups of RIN 6 are indicated in 
Figure 4. 
 
 Renal cell carcinoma 
RNA Samples with RIN ≤7 and >7 
(n=39/n=22) 
Samples with RIN ≤6> and >6 
(n=28/n=33) 
 P-values between the two RIN 
groups within the quantifications 
P-values between the two RIN 









circEGLNN3 <0.0001 0.006 <0.0001 <0.0001 
linEGLN3 <0.0001 0.0272 <0.0001 <0.0004 
circRHOBTB3 0.0003 0.3595 <0.0001 0.2122 
linRHOBTB3 0.0252 0.5434 0.0052 0.7473 
 Prostate cancer 
RNA Samples with RIN ≤7 and >7 
(n=38/n=19) 
Samples with RIN ≤6> and >6 
RIN limit ≤6> (n=26/n=31) 
 P-values between the RIN groups 
within the quantifications 
P-values between the RIN groups 









circCSNK1G3 0.0104 0.8208 0.0021 0.6390 
linCSNK1G3 <0.0001 0.1384 <0.0001 0.3411 
circRHOBTB3 <0.0001 0.2611 <0.0001 0.0976 
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Table S13. Regression line analysis of circRNAs and their linear counterparts calculated as relative 
quantities (RQ) and normalized relative quantities (NRQs) in relation to the RIN values of total RNA 













circEGLN3     
 RQ (2.3-9.4) Y = 0.9455*X - 2.188 0.5431 to 1.348 <0.0001 
<0.0001 
 NRQ (2.3-9.4) Y = 0.4433*X + 0.1145 0.1120 to 0.7746 0.0096 
 RQ (6.1-9.4) Y = -0.2766*X + 7.750 -1.564 to 1.011 0.6644 
0.7462 
 NRQ (6.1-9.4) Y = -0.5372*X + 8.053 -1.545 to 0.4703 0.2852 
linEGLN3     
 RQ (2.3-9.4) Y = 0.6381*X - 1.606 0.4427 to 0.8335 <0.0001 
0.0041 
 NRQ (2.3-9.4) Y = 0.2615*X + 0.2944 0.09397 to 0.4291 0.0028 
 RQ (6.1-9.4) Y = 0.2046*X + 1.969 -0.4299 to 0.8391 0.5156 
0.4644 
 NRQ (6.1-9.4) Y = -0.08939*X + 3.176 -0.6001 to 0.4214 0.7236 
circRHOBT3     
 RQ (2.3-9.4) Y = 0.3908*X - 0.7319 0.1925 to 0.5891 0.0002 
0.0093 
 NRQ (2.3-9.4) Y = 0.07253*X + 0.9296 -0.06392 to 0.2090 0.2919 
 RQ (6.1-9.4) Y = 0.04727*X + 2.055 -0.6825 to 0.7770 0.8958 
0.7929 
 NRQ (6.1-9.4) Y = -0.06250*X + 2.025 -0.4961 to 0.3711 0.7708 
linRHOBTB3     
 RQ (2.3-9.4) Y = 0.3033*X - 0.2363 0.1124 to 0.4941 0.0023 
0.0159 
 NRQ (2.3-9.4) Y = 0.000459*X + 1.426 -0.158 to 0.159 0.9954 
 RQ (6.1-9.4) Y = 0.02537*X + 1.964 -0.6619 to 0.7126 0.9405 
0.7489 
 NRQ (6.1-9.4) Y = -0.08375*X + 2.012 -0.5157 to 0.3482 0.6952 
RQ: relative quantification; NRQ: normalized relative quantification using the reference genes PPIA 
and TBP. The numbers in brackets (2.3-9.4) and (6.1-9.4) refer to the total RNA samples with the 
ranges of RIN values used for relative or normalized relative quantification.  
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Supplemental Table S14. Regression line analysis of circRNAs and their linear counterparts 
calculated as relative and normalized quantities in relation to the RIN values of total RNA samples 
from prostate cancer in Figure 5B. 








circCSNK1G3     
 RQ (2.2-8.2) Y = 0.1689*X + 0.2721 0.06446 to 0.2734 0.0020 
0.0491 
 NRQ (2.2-8.2) Y = 0.04611*X + 0.8797 -0.03305 to 0.1253 0.2481 
 RQ (6.3-8.2) Y = 0.1673*X + 0.2970 -0.4058 to 0.7404 0.5551 
0.4206 
 NRQ (6.3-8.2) Y = -0.09948*X + 1.871 -0.4519 to 0.2529 0.5682 
linCSNK1G3     
 RQ (2.2-8.2) Y = 0.1583*X + 0.2697 0.08914 to 0.2274 <0.0001 
0.0015 
 NRQ (2.2-8.2) Y = 0.03401*X + 0.8372 0.000987 to 0.06704 0.0438 
 RQ (6.3-8.2) Y = 0.4374*X - 1.712 0.1384 to 0.7364 0.0056 
0.0702 
 NRQ (6.3-8.2) Y = 0.1067*X + 0.3027 -0.05119 to 0.2645 0.1775 
circRHOBT3     
 RQ (2.2-8.2) Y = 0.2821*X - 0.2899 0.2084 to 0.3557 <0.0001 
0.0160 
 NRQ (2.2-8.2) Y = 0.1423*X + 0.4346 0.05470 to 0.2300 0.0019 
 RQ (6.3-8.2) Y = 0.5899*X - 2.537 0.2227 to 0.9571 0.0027 
0.0808 
 NRQ (6.3-8.2) Y = 0.1244*X + 0.4702 -0.2659 to 0.5146 0.5196 
linRHOBTB3     
 RQ (2.2-8.2) Y = 0.2200*X + 0.01879 0.1336 to 0.3063 <0.0001 
0.0089 
 NRQ (2.2-8.2) Y = 0.08193*X + 0.6510 0.02423 to 0.1396 0.0062 
 RQ (6.3-8.2) Y = 0.5374*X - 2.267 0.1721 to 0.9027 0.0054 
0.0691 
 NRQ (6.3-8.2) Y = 0.1514*X + 0.1060 -0.06801 to 0.3709 0.1688 
RQ: relative quantification; NRQ: normalized relative quantification using the reference genes ALAS1 
and HPRT1. The numbers in brackets (2.2-8.2) and (6.3-8.2) after RQ and NRQ refer to the total RNA 
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